Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 5, 2013, Pages 530-533

  Kantarjian, Hagop M ^a   O'Brien, Susan ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CML; Homoharringtonine (HHT); Omacetaxine mepesuccinate; Treatment

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE;

ACUTE GRANULOCYTIC LEUKEMIA; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

CML; HOMOHARRINGTONINE (HHT); OMACETAXINE MEPESUCCINATE; TREATMENT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG APPROVAL; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOID; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84884126310     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.03.017     Document Type: Review

References (41)

1. R.G. Powell, D. Weisleder, and C.R. Smith Jr. Structures of harringtonine, isoharringtonine, and homoharringtonine Tetrahedron Lett 11 1970 815 818
2. [No authors listed] Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment Chin Med J (Engl) 2 1976 263 272
3. Leukemia Research Group of the Chinese Liberation Army 187th Hospital. An analysis of 72 cases of leukemia treated with cephalotaxus ester alkaloid [in Chinese] J Chin Acad 58 1978 163 166 1978 [NIH library translation (NIH Pub No. 79-479)]
4. Z. Zhang, and C. Hou Clinical analysis of the therapeutic effects of semisynthetic harringtonine in treating 55 cases of non-lymphocytic leukemia [in Chinese] Chin J Intern Med 20 1981 667 669 [NIH library translation (NIH Pub. No. 87-168)]
5. Z. Shang Treatment of acute leukemia with harringtonine, semisynthetic harringtonine or total alkaloids of cephalotaxus hainanesis: analysis of curative results in 46 cases [in Chinese] Chung Hua Erh K O Tsa Chi 19 1981 (abstract 233) [NIH library translation (NIHPub. No. 87-166)]
6. Z.Y. Zhang, C.H. Hou, and Y.F. Zhu A preliminary therapeutic analysis of 82 cases of chronic granulocytic leukemia treated with harringtonine [in Chinese with English abstract] Chin J Intern Med 25 1986 156 157
7. J. Robin, R. Dhal, and G. Dujardin The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety Tetrahedron Lett 40 1999 2931 2934
8. J.L. Grem, B.D. Cheson, and S.A. King Cephalotaxine esters: anti-leukemic advance or therapeutic failure? J Natl Cancer Inst 80 1988 1095 1103
9. H.M. Kantarjian, M. Talpaz, and V. Santini Homoharringtonine. History, current research, and future directions Cancer 92 2001 1591 1605
10. A. Quintas-Cardama, H. Kantarjian, and J. Cortes Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009 Cancer 115 2009 5382 5392
11. P.J. O'Dwyer, S.A. King, and D.F. Hoth Homoharringtonine - perspective on an active new natural product J Clin Oncol 4 1986 1563 1568
12. J. Liu, Y. Mi, and M. Fu Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute leukemia Am J Hematol 84 2009 422 427
13. J. Jin, J. Wang, and F. Chen Homoharringtonine-based induction regimens for patients with de novo acute myeloid leukemia: a multicenter randomized controlled phase 3 trial Blood 120 2012 (abstract 45)
14. L. Wu, X. Li, and J. Su Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute leukemia transformed from myelodysplastic syndrome Leuk Lymphoma 50 2009 1461 1467
15. J.S. Ye, X.H. Wang, and G.H. Feng Small-dose harringtonine induces complete remission in patients with acute promyelocytic leukemia Leukemia 2 1988 427 429
16. L.H. Li, S.P. Lin, and Y.Y. Liang Harringtonine in treatment of polycythemia vera [in Chinese] Chin J Intern Med 23 1984 413 415 [NIH library translation (NIH Pub. No. 4-415)]
17. C.H. Hou, and Z.Y. Zhang Chinese People's Liberation Army 187th Hospital. Intrathecal injection of harringtonine and homoharringtonine in treating central nervous system leukemia -clinical analysis in 26 cases [in Chinese] J Chin Acad 61 1981 530 532 [NIH library translation (NIH Pub. No. 87-43)]
18. S.S. Legha, M. Keating, and S. Picket Phase I clinical investigation of homoharringtonine Cancer Treat Rep 68 1984 1085 1091
19. R.P. Warrell Jr., C.J. Coonley, and T.S. Gee Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia J Clin Oncol 3 1985 617 621
20. Z. Arlin, E. Feldman, and S. Biguzzi Phase I/II trial of homoharringtonine in acute leukemia Proc Am Soc Clin Oncol 6 1987 160
21. J.A. Stewart, P.A. Cassileth, and J.M. Bennett Continuous infusion homoharringtonine (NSC 141633 in refractory acute nonlymphocytic leuikemia. An ECOG pilot study Am J Clin Oncol 11 1988 627 629
22. E. Feldman, Z. Arlin, and T. Ahmed Homoharringtonine is safe and effective for patients with acute myelogeous leukemia Leukemia 6 1992 1185 1188
23. E.J. Feldman, K.P. Seiter, and T. Ahmed Homoharringtonine in patients with myelodysplastic syndrome (MDS) and mMDS evolving to acute myeloid leukemia Leukemia 10 1996 40 42
24. H.M. Kantarjian, M.J. Keating, and R.S. Walters Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia Cancer 63 1989 813 817
25. S. O'Brien, H. Kantarjian, and M. Keating Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase Blood 86 1995 3322 3326
26. S. O'Brien, H. Kantarjian, and C. Koller Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia Blood 93 1999 4149 4153
27. H.M. Kantarjian, M. Talpaz, and T.L. Smith Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia J Clin Oncol 18 2000 3513 3521
28. R.M. Stone, K.A. Donohue, and W. Stock Cancer and Leukemia Group B, a phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804 Cancer Chemother Pharmacol 63 2009 859 864
29. S. O'Brien, M. Talpaz, and J. Cortes Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia Cancer 94 2002 2024 2032
30. S. O'Brien, F. Giles, and M. Talpaz Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase Cancer 98 2003 888 893
31. J. Cortes, J.H. Lipton, and D. Rea Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation Blood 120 2012 2573 2580
32. J. Cortes, F. Nicollini, and M. Wetzler Subcutaneous omacetaxine in chronic or accelerated chronic myeloid leukemia resistant to two or more tyrosine-kinase inhibitors including imatinib Blood 118 suppl 1 2011 (abstract 2761)
33. D. Marin, J.S. Kaeda, and C. Andreasson Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib Cancer 103 2005 1850 1855
34. A. Quintas-Cardama, H.M. Kantarjian, and W. Wierda A phase II study of intravenous (IV) homoharringtonine (HHT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML) Blood 108 2006 (abstract 2174)
35. A. Quintas-Cardama, H. Kantarjian, and G. Garcia-Manero Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy Cancer 109 2007 248 255
36. F. Maloisel, P. Rousselot, and R. Morariu Subcutaneous hemisynthetic homoharringtonine (HHT) in combination with imatinib mesylate (Gleevec) in patients (PTS) with STI-resistant chronic myelogenous leukemia (CML): preliminary results of a pilot study Blood 102 2003 (abstract 909a)
37. C. Burton, A. Ranger, and E. Nedal Semi-synthetic homoharringtonine (Myelostat®) for chronic myeloid leukemia in accelerated phase after imatinib failure Blood 102 2003 (abstract 908a)
38. H. de Lavallade, J.S. Khorashad, and H.P. Davis Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation Blood 110 2007 2779 2780
39. L. Legros, S. Hayette, and F.E. Nicolini BCR-ABL (T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia 21 2007 2204 2206
40. Y. Chen, Y. Hu, and S. Michaels Inhibitory effects of homoharringtonine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice Blood 110 2007 (abstract 2912)
41. Brown D, Michaels S. Design and evaluation of oral delivery dosage forms of homoharringtonine. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research: April 14-18, 2007; Los Angeles, CA 2007; (abstract 4730).